Brain FDG & Dementia Imaging

Quick Answer

Brain FDG-PET shows regional glucose hypometabolism whose pattern helps differentiate dementia subtypes: temporoparietal + posterior cingulate/precuneus in Alzheimer disease, frontal/anterior temporal in frontotemporal dementia, and occipital involvement with a relatively preserved posterior cingulate (the "cingulate island sign") in dementia with Lewy bodies. Amyloid PET and tau PET image the underlying pathology directly — a negative amyloid scan makes Alzheimer pathology unlikely — and DAT SPECT supports dementia with Lewy bodies.

Definition

The neurodegenerative dementias are progressive disorders of acquired cognitive decline sufficient to impair daily function, caused by distinct molecular pathologies. The major entities imaged in nuclear medicine are Alzheimer disease (AD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and vascular dementia, with frequent mixed pathology in older patients.

Synonyms

Major/mild neurocognitive disorder; Alzheimer disease (AD); frontotemporal dementia / lobar degeneration (FTD/FTLD) including behavioral-variant (bvFTD) and primary progressive aphasias (PPA); dementia with Lewy bodies (DLB); vascular cognitive impairment.

Epidemiology

Alzheimer disease is the most common cause of dementia, followed by vascular and Lewy-body disease; FTD is a leading cause of younger-onset (< 65) dementia. Prevalence rises steeply with age, making dementia a growing public-health burden. Mixed AD–vascular pathology is very common at autopsy in the elderly.

Etiology & Risk Factors

• Age — the dominant risk factor across subtypes.
• AD: APOE ε4 dosage, family history, cardiovascular/metabolic risk; rare autosomal-dominant early-onset forms (APP, PSEN1, PSEN2); Down syndrome (trisomy 21, extra APP).
• FTD: strong heritability — C9orf72, MAPT, GRN.
• DLB: overlaps Parkinson disease biology (α-synuclein; GBA, SNCA).
• Vascular: hypertension, diabetes, atrial fibrillation, prior stroke.

Pathophysiology

• Alzheimer disease: extracellular β-amyloid plaques and intracellular neurofibrillary tau tangles, with synaptic failure and downstream temporoparietal/posterior-cingulate hypometabolism. The "amyloid cascade" posits amyloid as an early, upstream event with tau more closely tracking neurodegeneration and symptoms.
• DLB: α-synuclein Lewy bodies and nigrostriatal dopaminergic degeneration (basis for abnormal DAT SPECT), with occipital hypometabolism.
• FTD: tau or TDP-43 proteinopathy with frontal/anterior-temporal degeneration.
• Vascular: cumulative ischemic injury producing territorial/scattered deficits.

Genetics & Molecular Biology

• AD: APOE ε4 (risk), and deterministic APP/PSEN1/PSEN2 (early-onset autosomal-dominant).
• FTD: C9orf72 hexanucleotide expansion (also ALS), MAPT (tau), GRN (progranulin).
• DLB/PD spectrum: GBA, SNCA.
• The A/T/(N) biomarker framework (amyloid / tau / neurodegeneration) increasingly defines AD biologically — with amyloid and tau PET and CSF/plasma markers as the readouts.

Histopathology

Amyloid plaques and neurofibrillary tangles staged by Braak topography (AD); Lewy bodies (DLB); Pick bodies or TDP-43 inclusions (FTLD subtypes); ischemic/gliotic change (vascular). These map onto the imaging patterns below.

Clinical Presentation

• AD: insidious amnestic decline (episodic memory), later visuospatial and executive dysfunction.
• FTD: early behavioral/personality change (bvFTD) or progressive language decline (PPA), with relative memory sparing early.
• DLB: fluctuating cognition, visual hallucinations, parkinsonism, and REM-sleep behavior disorder; neuroleptic sensitivity.
• Vascular: stepwise decline, focal signs, and executive/processing slowing.

Laboratory & Fluid Biomarkers

CSF Aβ42 (↓), total-tau and phospho-tau (↑) in AD; emerging plasma p-tau217/181 and Aβ ratios are increasingly accurate blood biomarkers. APOE genotyping informs risk and anti-amyloid-therapy safety.

Imaging Findings by Modality

• MRI: atrophy patterns — hippocampal/medial-temporal (AD), frontal/anterior-temporal (FTD); small-vessel disease/infarcts (vascular). Also the safety modality for anti-amyloid-therapy ARIA monitoring.
• FDG-PET: subtype-specific hypometabolism patterns (table below) — the metabolic consequence.
• Amyloid PET / Tau PET: the molecular cause (see the amyloid & tau tracer page).
• DAT SPECT (ioflupane): reduced striatal uptake supports DLB (and parkinsonian syndromes) over AD.
• Perfusion SPECT (HMPAO/ECD) and cardiac MIBG (reduced in DLB) are supportive where PET is unavailable.

FDG Hypometabolism Patterns

Radiopharmaceutical Uptake Mechanisms

FDG reflects synaptic glucose metabolism, reduced where neurodegeneration impairs function. Amyloid ligands bind β-pleated-sheet plaque; tau ligands bind paired-helical-filament tau; DAT ligands (ioflupane) bind the presynaptic dopamine transporter on nigrostriatal terminals (reduced in Lewy-body/parkinsonian disease). Cardiac MIBG reflects postganglionic sympathetic denervation (reduced in DLB).

Typical PET Tracers

Typical SPECT Tracers

Therapy Indications

• Symptomatic: cholinesterase inhibitors (AD, DLB) and memantine (moderate–severe AD).
• Disease-modifying (AD): anti-amyloid monoclonal antibodies (lecanemab, donanemab) — requiring amyloid-positive confirmation for selection and serial MRI for ARIA (amyloid-related imaging abnormalities) safety monitoring.
• DLB: avoid typical neuroleptics (severe sensitivity); treat parkinsonism/RBD symptomatically.
• Vascular: risk-factor control.

Theranostics (Imaging-to-Treat)

Dementia's "image-to-select" pairing is amyloid PET → anti-amyloid therapy: a positive amyloid scan is now a prerequisite for eligibility, and tau PET stratifies stage/burden. This mirrors oncologic theranostics conceptually — confirm the target before treating it — with MRI-based ARIA surveillance as the safety counterpart.

Differential Diagnosis

• Reversible/secondary cognitive impairment: depression ("pseudodementia"), normal-pressure hydrocephalus, thyroid/B12 deficiency, medication effect, sleep/OSA.
• Among neurodegenerative types, overlap and mixed pathology are common; a single modality rarely settles it.
• Prion disease and autoimmune/limbic encephalitis in rapidly progressive cases.

Reporting Checklist

• Describe the FDG hypometabolism pattern and name the favored subtype(s).
• For amyloid: positive vs negative per approved visual criteria; avoid over-reading nonspecific white-matter uptake.
• Integrate DAT SPECT where DLB is considered.
• State the anti-amyloid-therapy context (selection/ARIA) when relevant, and acknowledge mixed pathology.

Prognosis

Neurodegenerative dementias are progressive; rate varies by subtype and comorbidity. Biomarker-positive AD progresses along the amyloid→tau→neurodegeneration axis, with tau burden/topography tracking clinical stage most closely. DLB carries added risks (falls, neuroleptic sensitivity, autonomic dysfunction). Disease-modifying therapy modestly slows early AD in selected, amyloid-positive patients.

Board Pearls

FDG shows the metabolic consequence and its pattern localizes the subtype — temporoparietal + posterior cingulate/precuneus (AD), frontal ± anterior temporal (FTD), occipital with a spared posterior cingulate (cingulate island sign, DLB) — while amyloid/tau PET image the cause directly.

A negative amyloid PET effectively excludes significant amyloid and therefore Alzheimer pathology — a high-value rule-out; a positive scan is less specific (amyloid rises with age) and is read with the clinical picture and tau PET. Reduced striatal DAT uptake supports DLB over AD.

In the anti-amyloid-therapy era, amyloid PET is an image-to-select gate (positivity required for eligibility) and MRI monitors ARIA. Read FDG accounting for atrophy, sedation, and glucose state, and remember mixed pathology is common — patterns overlap, and combining FDG + amyloid/tau + DAT resolves most ambiguous cases.

Related Pages

• Tracer: Amyloid & tau PET agents and FDG; ioflupane (DaTscan).
• Related: Epilepsy brain PET/SPECT and brain perfusion agents.
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A four-pattern FDG plate (AD vs FTD vs DLB vs vascular) with the cingulate island sign annotated.
• The A/T/(N) biomarker schematic mapping amyloid/tau/neurodegeneration to PET/CSF/plasma readouts.
• An amyloid-PET positive vs negative teaching pair (loss of gray–white distinction vs preserved).

Common Pitfalls

• Tau-PET (flortaucipir) off-target binding — choroid plexus, basal ganglia/striatum, and MAO-B–related uptake — can be misread as neurofibrillary tau; know the physiologic pattern.
• Crossed cerebellar diaschisis, remote infarct, or a subacute seizure can produce hypometabolism distant from the true dementing process — a localization trap.
• The DLB occipital pattern can be mimicked by inadequate visual stimulation (eyes closed) during the uptake phase — standardize scanning conditions.
• After anti-amyloid antibody therapy, amyloid-PET signal can fall — a post-treatment "negative" scan does not exclude underlying Alzheimer pathology.

Self-Check (Board-Style)